Development of an allergen extract for sublingual immunotherapy - Evaluation of Staloral

Expert Opinion on Biological Therapy

Volumn 9, Issue 9, 2009, Pages 1207-1215

  Frati, Franco ^a   Scurati, Silvia ^a   Puccinelli, Paola ^a   Justicia, José Luis ^b   Adamec, Thomas ^c   Sieber, Hans Jochen ^d   Ras, Lisbeth ^e   David, Marie ^f   Marcucci, Francesco ^g   Incorvaia, Cristoforo ^h  

^a Medical and Scientific Department   (Italy)

^b Medical Department   (Spain)

^c Stallergenes   (Czech Republic)

^d Medical Department   (Germany)

^e Medical Department   (Netherlands)

^f Medical Department   (France)

^g UNIVERSITY OF PERUGIA   (Italy)

^h ICP Hospital   (Italy)

Author keywords

Allergen extracts; Efficacy; High dose; Safety; Staloral; Sublingual immunotherapy

Indexed keywords

ANTIALLERGIC AGENT; PLACEBO; STALORAL; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; MAINTENANCE DRUG DOSE; MOUTH MUCOSA; POLLEN ALLERGY; REVIEW; T LYMPHOCYTE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; TONGUE;

ACARI; PYROGLYPHIDAE;

EID: 68949159772     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903146869     Document Type: Review

References (76)

1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet 1998;351:1225-1232
2. Galassi C, De Sario M, Biggeri A, et al. Changes in prevalence of asthma and allergies among children and adolescents in Italy: 1994-2002. Pediatrics 2006;117:34-42
3. Meltzer EO, Szwarcberg J, Pill MW. Allergic rhinitis, asthma, and rhinosinusitis: diseases of the integrated airway. J Manag Care Pharm 2004;10:310-317
4. Bousquet J, Lockey RF, Malling HJ, editors. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(Suppl 44):1-42
5. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111:437-448
6. Wilson DR, Torres-Lima M, Durham S. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4-12
7. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis and asthma due to house dust mite. Clin Allergy 1986;16:483-491 (Pubitemid 16006675)
8. Norman PS. Why standardized extract? J Allergy Clin Immunol 1986;77:405-406
9. Platts Mills TA, Chapman MD. Allergen standardization. J Allergy Clin Immunol 1991;87:621-625
10. Becker WM, Vogel L, Vieths S. Standardization of allergen extracts for immunotherapy: where do we stand? Curr Opin Allergy Clin Immunol 2006;6:470-475
11. American Medical Association, Current Procedural Terminology (CPT) 2005 standard edition, Chicago, American Medical Association, 2005
12. Passalacqua G, Villa G, Altrinetti V, et al. Sublingual swallow or spit? Allergy 2001;56:578
13. Marogna M, Spadolini I, Massolo A, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol 2007;98:274-280 (Pubitemid 46417574)
14. Dunsky E, Goldstein MF, Dvorin MJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006;61:1235
15. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007;62:567-568 (Pubitemid 46608356)
16. Passalacqua G, Valovirta E, van Weissenbruch R, et al, editors, Sublingual specific immunotherapy. From scientific background to clinical practice. Milan, Sinergie: 2007
17. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005;95:254-258 (Pubitemid 41376795)
18. Rossi R, Monasterolo RE. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005;18:277-285 (Pubitemid 40825890)
19. Tripodi S, Di Rienzo Businco A, et al. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2005;139:149-152 (Pubitemid 43177327)
20. Ariano R, Incorvaia C, La Grutta S, et al. Safety of sublingual immunotherapy started during the pollen season. Curr Med Res Opin 2009;25:103-107
21. Cadario G, Ciprandi G, Di Cara G, et al. Comparison between continuous or intermittent schedules of sublingual immunotherapy for house dust mites: effects on compliance, patients satisfaction, quality of life and safety. Int J Immunopathol Pharmacol 2008;21:471-473 (Pubitemid 351988414)
22. Clavel R, Bousquet J, André C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo controlled trial of a standardized five grass-pollen extract in rhinitis. Allergy 1998;53:493-498 (Pubitemid 28248417)
23. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:179-186
24. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol 1990;10:277-284
25. Bousquet J, Van Cauwenberge P, editors. Allergic rhinits and its impact on asthma (ARIA). J Allergy Clin Immunol 2001;108(Suppl 5):S146-50 (Pubitemid 33127203)
26. Sabbah A, Hassoun S, Le Sellin J, et al. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309-313 (Pubitemid 24163858)
27. Pradalier A, Basset D, Claudel A, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999;54:819-828 (Pubitemid 29402164)
28. Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662-672 (Pubitemid 28319999)
29. La Rosa M, Ranno C, André C, et al. Double blind placebo controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425-432 (Pubitemid 29420442)
30. André C, Perrin-Fayol M, Grosclaude M, et al. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003;131:111-118
31. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004;93:425-430 (Pubitemid 39507708)
32. Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch-pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:45-53 (Pubitemid 38167951)
33. Di Rienzo V, Pucci S, D'Alò S, et al. Effects of high dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: a placebo-controlled study. Clin Exp Allergy Rev 2006;6:67-70
34. Vervloet D, Birnbaum J, Laurent P, et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol 2007;142:239-246
35. Lue KH, Lin YH, Sun HL, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006;17:408-415
36. Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double-blind, placebo-controlled study. Allergy 1999;54:249-260 (Pubitemid 29185286)
37. Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: a placebo-controlled study. Ann Allergy Asthma Immunol 1999;82:485-490 (Pubitemid 29242317)
38. Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32:49-55
39. Mortemousque B, Bertel F, De Casamayor J, et al. House dust mite sublingual swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2003;33:464-469 (Pubitemid 36520909)
40. Tonnel AB, Scherpereel A, Douay B, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004;59:491-497 (Pubitemid 38580768)
41. Niu CK, Chen WY, Huang JL, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo controlled study in Taiwan. Respir Med 2006;100:1374-1383
42. Guez S, Vatrinet C, Fadel R, André C. House dust mite sublingual swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000;55:369-375 (Pubitemid 30183056)
43. Pham-Thi H, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007;18:47-57 (Pubitemid 46232283)
44. Calamita Z, Saconato H, Pel AB, Atallah N. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration Method. Allergy 2006;61:1162-1172 (Pubitemid 44326350)
45. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97(2):141-148 (Pubitemid 44272577)
46. Penagos M, Passalacqua G, Compalati E, et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609
47. Marcucci F, Sensi L, Dicara G, et al. Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005;60:952-956
48. Frati F, Sensi L, Di Rienzo V, et al. A model for management of sublingual immunotherapy. Eur Ann Allergy Immunol 2003;35:56-60
49. André C, Vatrinet C, Galvain S, et al. Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121:229-234 (Pubitemid 30157710)
50. Gidaro GB, Marcucci F, Sensi L, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005;35:565-571 (Pubitemid 40769278)
51. Incorvaia C, Frati F, Puccinelli P, et al. Dose dependence of efficacy and safety of subcutaneous immunotherapy. Monaldi Arch Chest Dis 2006;65:41-43 (Pubitemid 43676459)
52. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007;62:567-568 (Pubitemid 46608356)
53. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008;63:374 (Pubitemid 351224673)
54. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007;119:780-791
55. Romagnani S. Regulation of the T cell response. Clin Exp Allergy 2006;36:187-196
56. Taylor A, Verhagen J, Blaser K, et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology 2006;117:433-442
57. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-713 (Pubitemid 47320765)
58. Incorvaia C, Frati F. On mechanism of action of sublingual immunotherapy. Pediatr Allergy Immunol 2009;20:102
59. Noirey N, Rougier N, André C, et al. Langerhans-like dendritic cells generated from cord blood progenitors internalize pollen allergens by macropinocytosis, and part of the molecules are processed and can activate autologous naive T lymphocytes. J Allergy Clin Immunol 2000;105:1194-1201 (Pubitemid 30418800)
60. Marcucci F, Sensi L, Incorvaia C, et al. Oral reactions to sublingual immunotherapy: a bioptic study. Allergy 2007;62:1475-1477 (Pubitemid 350045595)
61. Marcucci F, Incorvaia C, Sensi L, et al. Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol 2008;21:609-613
62. Frati F, Moingeon P, Marcucci F, et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc 2007;28:35-39
63. Incorvaia C, Mauro M, Ridolo E, et al. Patient's compliance with allergen immunotherapy. Patient Preference Adherence 2008;2:247-251
64. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993;91:734-737 (Pubitemid 23110718)
65. Lower T, Henry J, Mandik L, et al. Compliance with allergen immunotherapy. Ann Allergy Asthma Immunol 1993;70:480-482
66. Rhodes BJ. Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol 1999;82:281-286
67. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-857 (Pubitemid 39330257)
68. Marogna M, Spadolini I, Massolo A, et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004;59:1205-1210 (Pubitemid 39389476)
69. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy regimen in real life EASY project: evaluation of a novel SLIT formulation during a year. J Allergy Clin Immunol 2006;117:946-948
70. Lombardi C, Gani F, Landi M, et al. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol 2004;113:1219-1220 (Pubitemid 38858010)
71. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with once daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol 2007;18:56-62 (Pubitemid 46232284)
72. Passalacqua G, Frati F, Puccinelli P, et al. Adherence to sublingual immunotherapy: the allergist's viewpoint. Allergy (In Press)
73. Berto P, Bassi M, Incorvaia C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol 2005;37:303-308 (Pubitemid 41599772)
74. Berto P, Passalacqua G, Crimi N, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: The Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006;97:615-621 (Pubitemid 44851458)
75. Berto P, Frati F, Incorvaia C, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. Curr Med Res Opin 2008;24:261-266 (Pubitemid 351160258)
76. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol 2008;8:585-589